Content uploaded by Bryant Villeponteau
Author content
All content in this area was uploaded by Bryant Villeponteau on Jul 17, 2018
Content may be subject to copyright.
page 1 of 9ISSN:XXXX-XXXX SFJHM, an open access journal
Volume 2 · Issue 1 · 1000010SF J Herb Med
Research Article Open Access
Publishers
SCIFED
SciFed Journal of Herbal Medicine
Bryant Villeponteau, SF J Herb Med, 2018, 2:1
Multipath Herbal Nutraceutical Improves Self-Reported Markers of
Health and Life Expectancy in Clinical Study
*1Bryant Villeponteau
*1Centagen Inc., 637 S. Broadway St., Ste. B-206, Boulder, Colorado, 80305, USA
Abstract
Background
Research indicates that aging and health are affected by hundreds of biochemical pathways. The major goal
of this study was to test the effects of a multipath antiaging dietary supplement on healthy adults using markers of
health and life expectancy. While results on the clinical lab test markers from the study were published earlier, the
self-reported survey markers are reported herein.
Methods
The design of the dietary supplement intervention clinical study was an open-label field study. Fifteen men
and women aged 42 to 79 years took a 10 component dietary supplement SC100+ twice daily for 15 weeks. In self-
rated surveys taken at the end of the trial, the subjects reported their perceived changes with respect to 6 markers
of overall health (Overall Health, Ability to Concentrate, Joint Flexibility, Work Productivity, Ability to Relax, and
Immune Function) and 7 potential markers of life expectancy (Stress Tolerance, Energy Level, Endurance, Ease of
Walking, Climbing Stairs, Overall Mood, and Vitality). The survey also contained a key control marker (Skin Age
Spots) and two secondary control markers (Skin Wrinkles and Vision) that were expected to stay constant during the
15 week trial. Paired two-sided Student t-tests were performed to determine the significance of each marker rating
post treatment in comparison to the observed change in the key control marker. The survey results were also compared
with the significant changes after 15 weeks of multipath treatment on blood pressure, HDL Cholesterol, stress levels,
and lung capacity that were published previously.
Results
In the self-rated surveys taken at the end of the trial, the subjects rated 6 markers of overall health (Overall
Health, Ability to Concentrate, Joint Flexibility, Work Productivity, Ability to Relax, and Immune Function) and 7
potential markers of life expectancy (Stress Tolerance, Energy Level, Endurance, Ease of Walking, Climbing Stairs,
Overall Mood, and Vitality) as to the degree each marker changed for the better or worse. All of the test markers
appeared to significantly improve with respect to the control marker for skin aging spots, while the other secondary
control markers indicated no significant improvement. There were no reported side effects. The self-reported survey
markers follow a similar positive pattern observed with the clinical tests on blood pressure, HDL Cholesterol, stress
levels, and lung capacity from the same clinical trial that was recently published.
Conclusions
While larger placebo-controlled clinical studies are needed, this small pilot trial suggests that complex
multipath herbal supplements that target 8 to 10 aging pathways may have the potential to promote overall health
without generating significant side effects. The data also provide indirect support for the hypothesis that multipath
supplements like SC100+ may extend life expectancy.
page 2 of 9ISSN:XXXX-XXXX SFJHM, an open access journal
Volume 2 · Issue 1 · 1000010SF J Herb Med
Citation: Bryant Villeponteau (2018) Multipath Herbal Nutraceutical Improves Self-Reported Markers of Health and Life Expectancy in Clinical Study.
SF J Herb Med 2:1.
Keywords
Aging; Antiaging; Stress; Energy; Mood;
Concentration; Endurance; Concentration; Immune Function;
Work Productivity; Joint Flexibility; Ability to Relax
List of abbreviations
HDL: High-density lipoprotein
HRV: Heart rate variability
IRB: Institutional Review Board
PEF: Peak expiratory flow
SC100+: Stem Cell 100+
Background
Aging studies in many animal species have
reported over a hundred genes linked to the aging process.
These published results provide evidence for the Evolution
Theory of Aging [1, 2], which predicts that aging leads
to poorly functioning organisms as optimal gene function
and fitness decline with age after maturation to adulthood.
The fact that many genes have altered expression with
age suggests the hypothesis that a multipath treatment to
nudge the expression of many critical genes back toward
youthful fitness levels could promote rejuvenation in older
subjects. Since aging plays a major role in age-related
diseases and overall health, a multipath natural product
approach targeting critical genes involved in aging might
also promote overall health and extend life expectancy.
This multipath natural product supplement hypothesis
was tested in Drosophila aging and was successful in
significantly extending mean and maximum life span
[3]. Overall health as measured by enhanced fertility also
appeared to be improved by the multipath natural product
supplement [3].
To test this composite multipath hypothesis in
humans, we have completed a small open-label clinical
trial that treated 15 healthy subjects for 15 weeks with the
multipath nutraceutical supplement SC100+ containing 10
active components. In designing the SC100+ formulation,
the strategy was to target a critical number of the known
pathways linked to health, fitness, and longevity. The
independent targeted pathways included: adult stem cell
function, telomere loss, neural stress, diet or exercise
induced inflammation, insulin-like growth factors,
autophagy, vascular circulation, neural function, and
oxidative stress.
In formulating SC100+, we started our research
work with natural product extracts found in the herbal
multipath supplement that increased mean and maximum
lifespan in Drosophila [3] and then added other natural
product compounds known to act on other independent
age-related pathways. In adding additional nutraceuticals,
we identified the subset of nutraceuticals that have a
proven history of use in herbal medicine to treat pleotropic
human health conditions. we also identified the subset of
nutraceuticals that have little or no known side effects.
Finally, we focused on stem cell function as a critical factor
in rejuvenation [4-6] by screening candidate longevity
nutraceuticals for their effectiveness in stimulating and/or
maintaining adult stem cell growth in human tissue culture
screens. The final ten herbal extracts in SC100+ provide a
diverse set of bioactive natural products, which appear to
act on many of the critical health and longevity pathways,
as is specified in detail in the background to our previous
article on the treatment with SC100+ in the clinical trial
[7].
The ten SC100+ components are a set of
synergistic natural products that act on a critical number
of the longevity targets. In our previous publication,
we reported on objective lab tests (blood pressure, HDL
Cholesterol, heart rate variability as a measure of stress,
and lung capacity) from subjects at baseline and post
treatment with SC100+ [7]. In this article, I present the
self-reported surveys taken by the subjects at the end of
the trial that typify the changes in various makers linked to
health and life expectancy over the treatment period.
Materials and Methods
Multipath SC100+ dietary supplement and treatment
dose
*Corresponding author: Bryant Villeponteau, Centagen Inc., 637
S. Broadway St., Ste. B-206, Boulder, Colorado, 80305, USA.
E-mail: bvillepo@san.rr.com
Received November 24, 2017; Accepted December 26 2017; Published
January 10, 2018
Citation: Bryant Villeponteau (2018) Multipath Herbal Nutraceutical
Improves Self-Reported Markers of Health and Life Expectancy in
Clinical Study. SF J Herb Med 2:1.
Copyright: © 2018 Bryant Villeponteau. This is an open-access article
distributed under the terms of the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are credited.
page 3 of 9ISSN:XXXX-XXXX SFJHM, an open access journal
Volume 2 · Issue 1 · 1000010SF J Herb Med
Citation: Bryant Villeponteau (2018) Multipath Herbal Nutraceutical Improves Self-Reported Markers of Health and Life Expectancy in Clinical Study.
SF J Herb Med 2:1.
The patent-pending SC100+ dietary supplement
has the following 10 active natural products present in
each capsule: 1) Astragalus membranaceus root extract;
2) Rhodiola rosea root extract; 3) Vaccium Uliginosum
fruit extract standardized for resveratrol analogs; 4)
Tulsi leaf extract; 5) Pine Bark root extract standardized
for 94% Oligomeric-Proanthocyanidins; 6) L-Theanine;
7) Genistein; 8) Methyl Folate (300 mcg 5-MTHF); 9)
Methyl B12 (250 mcg Methylcobalamin); and 10) Vitamin
D3 (1000 IU). The recommended dose was two capsules
per day.
Study participants and design
The clinical trial described in this paper was a
small open-label pilot study on the effects of SC100+ on
health markers in male and female subjects 42 to 79 years
of age (mean of 57 years). The needed sample size for
some of the markers was calculated based on a smaller
pilot study with 5 subjects, wherein blood pressure and
cholesterol were measured at baseline and after 6 weeks
of treatment. The final trial patient size was determined
using an online power analysis calculator for systolic and
diastolic blood pressure, HDL Cholesterol, Lung function,
and Stress testing. The power analysis showed that a 90%
chance of detecting a 5% change in Blood pressure and
HDL Cholesterol required 13 to 15 patients, while a 5%
change in Lung Function or Stress levels required 5 to
6 patients. Therefore, our goal was a sample size of at
least 15 patients without a placebo control. Unfortunately,
project funding only allowed for 15 to 16 patients and
placebo controls would require almost double our available
funding. The open label pilot study was retrospectively
registered on Feb. 8, 2017 (NCT03052491).
Sixteen volunteers for the trial were recruited
publicly from Los Angeles and San Diego and the actual
trial was run March through August of 2016. One subject
dropped out in the first week due to unrelated medical
problems from doctor-prescribed hormone treatment. The
other 15 subjects completed 15 weeks on the SC100+
supplement without any reported side effects. SC100+
capsules were provided by Centagen, Inc. in Boulder, CO.
The selection criteria for the study volunteers
consisted of: 1) Excludes subjects younger than 35 years
or pregnant women; 2) No history of metastatic cancer,
heart attack, or dementia; 3) Currently healthy with no
life-threatening diseases; 4) Willing to undergo clinical
blood tests and other non-invasive tests at baseline and
after taking SC100+; 5) Committed to taking one SC100+
capsule twice daily for the test period; 6) Willing to sign
the IRB Research Participant Consent Form.
Subject Recruitment and Follow-Up
The recruitment period started in mid-February,
2016, and continued through early April of 2016. The first
subjects started baseline testing March 12, 2016, while
the last subject was baseline tested April 10, 2016. All
subjects had completed the final testing at the end of the
trial by August 14, 2016. Depending on their schedule,
SC100+ supplementation and follow up continued for an
average of 15 weeks with a minimum of 13.5 weeks and
a maximum of 16.5 weeks. All 15 subjects completed the
survey at the end of the test period.
Statistical Analysis
Results are expressed as mean +/- 95% t-test
confidence intervals. Paired two-sided Student t-tests
were performed to evaluate the significance of differences
between tested survey markers and the control age spot
marker that was not expected to change during the 15
week test. A p value of <0.05 was considered significant.
All statistical analyses were carried out with Microsoft
Excel and double checked using the commercial scientific
statistics software from GraphPad Software, Inc.
Results
SC100+ was tested in an open label pilot study
We have carried out an IRB approved clinical
trial using the 10 active component multipath formulation
SC100+ to treat human volunteers for a period of 15 week
duration. The pilot study was an open-labeled field trial
on healthy human subjects. Seven females and eight males
participated and completed the trial with no reported side
effects. The average age of the subjects was 57 with a
range of 42 to 79 years. Most subjects were in their 50s,
while 3 subjects were under 50 years of age and 2 subjects
were over 70.
The subjects were tested at baseline and after 15
weeks on SC100+ for the following: systolic and diastolic
arterial blood pressure, heart rate, total blood cholesterol,
HDL blood cholesterol, stress, lung capacity, and self-
rated health survey. For the intervention clinical trial, the
subjects were instructed to take one SC100+ capsule twice
daily at breakfast and dinner. During the clinical trial with
SC100+, the subjects were permitted to continue taking
their prescription drugs and any supplements that they had
previously been taking.
page 4 of 9ISSN:XXXX-XXXX SFJHM, an open access journal
Volume 2 · Issue 1 · 1000010SF J Herb Med
Citation: Bryant Villeponteau (2018) Multipath Herbal Nutraceutical Improves Self-Reported Markers of Health and Life Expectancy in Clinical Study.
SF J Herb Med 2:1.
Figure 1 shows a flow chart of the clinical trial.
Potential subjects were first contacted at youth soccer
matches or using the parental email lists of junior soccer
players. Twenty subjects expressed interest in joining the
trial and were assessed for eligibility. All 20 subjects were
deemed eligible. Three of the 20 subjects later declined
to participate and one subject moved away and was
thus unavailable for testing. The remaining 16 subjects
received a 60 day supply of SC100+. One subject dropped
out of the trial in the first week due to issues with hormone
replacement therapy that was added a few days before
starting the SC100+ study. The remaining 15 subjects
completed the trial. Lab tests for blood pressure, heart rate,
cholesterol, stress, and lung capacity were performed on
the 15 subjects at baseline and after 15 weeks on SC100+
and were reported in an earlier publication [7]. The self-
reported results are described below.
Self-Reported Surveys: SC100+ Promotes Index
Markers of Overall Health and Life Expectancy
On completion of 15 weeks on SC100+, the subjects
were asked to fill out an online survey to document their
self-rated evaluations after taking SC100+. In the survey
the subjects choose from a pull-down menu containing
the ratings for their perceived changes over the 15 weeks
taking the supplement: Much Better (Code = +3), Better
(Code = +2), Somewhat Better (Code = +1), Stayed the
Same (Code = 0), Somewhat Worse (Code = -1), Worse
(Code = -2), or Much Worse (Code = -3) for each index
marker. The markers were: Overall Health, Ability to
Concentrate, Joint Flexibility, Work Productivity, Ability
to Relax, Immune Function, Quality of Sleep, Bowel
Regularity, Weight Management, Hair and Nails, Age
Spots, Skin Wrinkles, Vision, Stress Tolerance, Energy
Level, Endurance, Ease of Walking, Ease of Climbing
Stairs, Overall Mood, and Vitality.
To simplify reporting on our analysis, I separated
the above markers into four broad categories, which are
shown on the left column of Table 1 as Overall Health,
Specialized Health Conditions, Controls, and Life
Expectancy. The index Markers of Overall Health included
the following health markers: Overall Health, Ability to
Concentrate, Joint Flexibility, Work Productivity, Ability
to Relax, and Immune Function. The Specialized Health
Conditions markers include Quality of Sleep, Bowel
Regularity, Weight Management, and Hair/Nails, which
are a specialized sub-group of Overall Health. The self-
reported mean ratings are shown in Table 1 along with the
ratings of three Control Index Markers (Age Spots, Skin
Wrinkles, and Vision), which were unlikely to change in 15
weeks of taking SC100+ and thus provided a placebo-like
check on subjects that might have been overly optimistic
in their perception of specific changes where no changes
actually occurred.
The self-reported survey of subject marker ratings
(Table 1) indicate that the mean ratings for Overall Health
markers (Overall Health, Ability to Concentrate, Joint
Flexibility, Work Productivity, Ability to Relax, and
Immune Function) were highly positive compared to
placebo-like claims of improvement in Age Spots (p<0.05).
In contrast, positive ratings for the Specialized Health
Conditions (Quality of Sleep, Bowel Regularity, Weight
Management, and Hair/Nails) were not significantly
changed relative to the placebo-like control marker for Age
Spots. The two other placebo-like index markers (Vision
and Skin Wrinkles) also did not change significantly
while taking SC100+. Finally, Table 1 also shows that the
hypothesized index markers for Life Expectancy (Stress
Tolerance, Energy Level, Endurance, Ease of Walking,
Climbing Stairs, Overall Mood, and Vitality) were all
rated as significantly improved with SC100+ treatment
relative to the rating for the placebo-like control marker
for Age Spots.
Lab Test versus Survey Values for Each Subject along
with Age and Gender Data
To check whether the lab tests on cardio health
(blood pressure, heart rate, and HDL Cholesterol) and
Stress/Lung tests from our previously published article [7]
tell a different story from the self-reported Health and Life
Exp surveys (shown in Table 1) or vary with age or gender,
I have compared the combined test and survey data for all
15 subjects in Table 2 below.
The combined scores in Table 2 allow us to analyze
many aspects of the differing data sets. First, I checked
whether the Health and Life Exp surveys give differing
results. A paired t test gave a value of p = 0.66, suggesting
the Health and Life Exp surveys do not give significantly
different results for the individual subjects. Likewise I
checked the Cardio and Stress/lung tests for significant
differences by pair t tests and found p = 0.32, suggesting
little significant differences in differing types of lab
measurements.
We next checked whether the combined lab tests
values for each subject are significantly different from
combined self-reported survey data (column 9 versus 8
page 5 of 9ISSN:XXXX-XXXX SFJHM, an open access journal
Volume 2 · Issue 1 · 1000010SF J Herb Med
Citation: Bryant Villeponteau (2018) Multipath Herbal Nutraceutical Improves Self-Reported Markers of Health and Life Expectancy in Clinical Study.
SF J Herb Med 2:1.
Figure 1: Participant Clinical Flow Diagram: The flow of subjects through each stage of the SC100+ clinical study is shown in the Clinical
Flow Diagram
Markers Outcome Measures Mean +/- 95% CI Paired t Test
Overall Health
Overall Health
Ability to Concentrate
Joint Flexibility
Work Productivity
Ability to Relax
Immune Function
1.87 +/- 0.354
1.80 +/- 0.374
1.00 +/- 0.513
1.60 +/- 0.585
0.93 +/- 0.532
1.47 +/- 0.692
p < 0.00001
p = 0.00001
p = 0.010
p = 0.0006
p = 0.036
p = 0.003
Special Conditions
Quality of Sleep
Bowel Regularity
Weight Management
Hair and Nails
0.53 +/- 0.411
0.60 +/- 0.520
0.80 +/- 0.630
0.60 +/- 0.504
p = 0.262
p = 0.334
p = 0.135
p = 0.173
Controls
Age Spots
Skin Wrinkles
Vision
0.27 +/- 0.254
0.40 +/- 0.281
0.40 +/- 0.408
Paired Control
p = 0.334
p = 0.546
Life Expectancy
Stress Tolerance
Energy Level
Endurance
Ease of Walking
Ease of Climbing Stairs
Overall Mood
Vitality
1.53 +/- 0.587
1.80 +/- 0.521
1.47 +/- 0.626
0.87 +/- 0.507
1.00 +/- 0.554
1.47 +/- 0.587
1.33 +/- 0.540
p = 0.0018
p < 0.00001
p = 0.0004
p = 0.033
p = 0.022
p = 0.005
p = 0.0007
Table1: SC100+ Promotes Improvement in Markers of Overall Health and Life Expectancy
page 6 of 9ISSN:XXXX-XXXX SFJHM, an open access journal
Volume 2 · Issue 1 · 1000010SF J Herb Med
Citation: Bryant Villeponteau (2018) Multipath Herbal Nutraceutical Improves Self-Reported Markers of Health and Life Expectancy in Clinical Study.
SF J Herb Med 2:1.
Table 1 is data derived from a self-reported survey at the end of the trial, where the subject rates his or her
perception of any benefit/harm after taking SC100+ using various index markers. The subject goes online
and chooses from a pull-down menu containing the ratings: Much Better (Code = +3), Better (Code = +2),
Somewhat Better (Code = +1), Stayed the Same (Code = 0), Somewhat Worse (Code = -1), Worse (Code =
-2), or Much Worse (Code = -3). The mean coded score is shown in column 3 for each outcome measure and
is shown with +/- the 95% Confidence Intervals (CI). The last column is the paired student t probability of
significance that compares each outcome measure versus the placebo-like Age Spots marker (shown as the
first Control Marker in Table 1).
Subject #
(sex) Age Compliant
Health
Survey
Life Exp
Survey
Cardio
Tests
Stress/Lung
Tests
All Sur-
veys
All
lab
Tests
Health
Survey
Life Exp
Survey
1 (F) 42 100% 9 8 10 ND 17 20 9 8
2 (F) 45 40% 3 6 4 7 9 11 3 6
3 (M) 45 100% 16 15 8 ND 31 18 16 15
4 (M) 52 75% 6 2 10 12 8 22 6 2
5 (M) 53 100% 10 9 13 ND 19 23 10 9
6 (F) 54 100% 12 11 10 12 23 22 12 11
7 (M) 54 100% 10 10 8 8 20 16 10 10
8 (F) 55 30% 4 1 5 8 5 13 4 1
9 (F) 56 100% 10 10 14 16 20 30 10 10
10 (M) 56 90% 9 6 14 11 15 25 9 6
11 (F) 58 100% 20 17 8 8 37 16 20 17
12 (M) 66 100% 5 10 17 10 15 27 5 10
13 (F) 69 100% 10 9 14 6 19 20 10 9
14 (M) 71 100% 9 15 16 14 24 30 9 15
15 (M) 79 100% 11 10 17 10 21 27 11 10
Mean 57 9.6 9.3 11.2 10.2 18.9 21.3 9.6 9.3
Table 2: Combined Lab Test and Survey Values for all subjects
Table 2 summarizes the Health and Life Exp (Life Expectancy) surveys by combining the self-reported
survey values for each subject (Columns 4 and 5). Likewise the combined Cardio (blood pressure, heart rate,
and HDL Cholesterol) and Stress/Lung tests are shown for each subject in columns 6 and 7. In setting values
for Cardio, blood pressure is given 8 points total (e.g. negative changes = 0, no change = 2, small positive
change = 4, positive mean change = 3, and 2X mean change = 4), heart rate is given 4 points total, and HDL
Cholesterol is given 8 points total using similar coding strategy. Column 8 combines the scores from the
Health and Life Exp surveys to calculate the All Surveys score. Column 9 combines both the Cardio and
Stress/lung scores to get the All Lab Tests score. ND = Not Done and mean Stress/Lung test average of 10
was used to obtain the All Lab Test Values in column 9 for the missing ND cases.
of Table 2) for each subject. The paired t tests for this
difference gave a p = 0.33, which suggest that the objective
lab tests give similar results to the self-reported surveys for
each subject.
We also tested whether the data is significantly
different if you compare the composite gender data for
males versus females: The non-paired t tests give a value
of p = 0.34, suggesting there are no significant difference
between male and female combined values.
Discussion
The self-reported survey results shown in Table 1
suggest that all of the ratings for markers affecting Overall
Health (Overall Health, Concentration, Joint Flexibility,
page 7 of 9ISSN:XXXX-XXXX SFJHM, an open access journal
Volume 2 · Issue 1 · 1000010SF J Herb Med
Citation: Bryant Villeponteau (2018) Multipath Herbal Nutraceutical Improves Self-Reported Markers of Health and Life Expectancy in Clinical Study.
SF J Herb Med 2:1.
Work Productivity, Ability to Relax, and Immune Function)
were significantly positive compared to placebo-like
claims of improvement in Age Spots (p<0.05). While one
should be cautious with self-reported data, these results
provide suggestive support for our hypothesis that SC100+
promotes overall health.
Like the markers for Overall Health, the proposed
markers for Life Expectancy (Stress Tolerance, Energy
Level, Endurance, Ease of Walking, Climbing Stairs,
Overall Mood, and Vitality) were significantly improved
compared to placebo-like claims of improvement in Age
Spots (p<0.05). Stress Tolerance and Endurance have both
been linked to longevity and all-cause mortality in both
animals and humans [8-11]. Other studies have shown that
higher scores on mobility and Activities of Daily Living
(ADL) are associated with lower all-cause mortality [12],
which link mobility markers like Energy level, Ease of
Walking, Ease of Climbing Stairs, and Vitality as indices
of life expectancy. Finally, Mood Disorders cause big
increases in mortality risks [13, 14]. The results in Table
1 indicate that all of these indirect life expectancy markers
are rated largely positive by SC100+ treated subjects.
The Table 1 results are further supported by our
previously published lab test data reporting that the same
SC100+ treatment significantly lowered blood pressure
and stress, while significantly raising HDL cholesterol and
lung function [7]. Blood pressure is an important indicator
of overall health and longer life [15]. Stress is very strong
predictor of overall health and all-cause mortality [10, 16-
18]. People with higher levels of HDL cholesterol have
lower risks of ill health, frailty, and total mortality, while
having higher physical performance levels and cognition
[19-22]. Lung function (as measured by peak expiratory
flow or PEF) has been shown to be a valid measure of
overall health status and all-cause mortality [23-27].
Table 2 combines the published lab test data on
blood pressure, stress, HDL cholesterol, and lung function
with the self-reported survey data for the individual
subjects. The accumulated data in Table 2 from both
the lab tests and survey data suggest that there is not a
significant difference in the results for the lab tests versus
the self-reported survey questions or males versus females
or differing responses with age. Thus, a subject who
scores very high on the lab test data is also likely to give
high ratings to markers of overall health or life expectancy.
Taken together, both the lab test data and the self-reported
survey data provide suggestive support for our hypothesis
that SC100+ promotes overall health and life expectancy.
One difference that does appear to be important
was compliance in taking the SC100+ supplement, as
the two females (subjects 2 and 8) with low treatment
compliance rates estimated at 40% and 30% compliance
respectively had about one half of the mean values of those
with 100% compliance (Table 2). This can be viewed as
an effect of low dosage of SC100+.
Limitations of this preliminary study are easy to
identify. First, this was an open-label clinical study without
a placebo test group. In practice, many of the variables
testing significant in the published study were objective
tests such as lung function, HDL Cholesterol, and HRV
tests [7], which typically test very low in placebo tests. In
the case of the self-reported surveys in Table 1, I included
survey questions that were not expected to change while
taking SC100+, so as to better determine the power of any
placebo effect on self-reported improvements.
A second limitation of the preliminary study is the
small size of 15 subjects. A larger trial would be needed to
have better confidence in these promising results. Despite
the small size, both genders were represented and all ages
in the 40s, 50s, 60s, and 70s were part of the trial and
showed positive trends with respect to the Overall Health
and Life Expectancy markers.
A third limitation of this pilot study is the short
duration of 15 weeks, which may not be long enough to
accurately measure sustained changes in the markers of
Life Expectancy. Some would argue that a study of 3 to 5
years would be needed to really determine what might be
happening with Life Expectancy.
Notwithstanding the possible limitations, this
study suggests that simultaneously targeting multiple
critical antiaging pathways has the potential to give
pleotropic beneficial effects to healthy people. Since most
age-related conditions and diseases have multiple causes,
this apparent success of addressing multiple genetic and
biochemical pathways simultaneously has important
implication for future clinical trials and current clinical
practice.
Declarations
Ethics approval and consent to participate
The clinical trial (IRCM-2016-091) was approved
for up to 20 subjects by the Institutional Review Board
(IRB) in the Institute of Regenerative and Cellular
Medicine on Feb. 25, 2016. Written informed consent for
the clinical trial was obtained from all volunteers prior
to baseline testing and the informed consent forms were
page 8 of 9ISSN:XXXX-XXXX SFJHM, an open access journal
Volume 2 · Issue 1 · 1000010SF J Herb Med
Citation: Bryant Villeponteau (2018) Multipath Herbal Nutraceutical Improves Self-Reported Markers of Health and Life Expectancy in Clinical Study.
SF J Herb Med 2:1.
approved by the IRB. The selection of subjects for the
study adhered to NIH guidelines.
Consent for publication
Not applicable
Availability of data and materials
The dataset generated and analyzed from the 15
individual subjects during the current study are included
in the current study as a PDF supporting file (see Clinical
Raw Data). As for the SC100+ dietary supplement,
contact info@Centagen.com for SC100+ research samples
or purchase the commercial version of SC100+ (Stem Cell
100+) online at www.Centagen.com .
Competing interests
BV is a cofounder, unpaid consultant, and equity
holder in Centagen. This does not alter the author’s
adherence to the policies on sharing data or materials.
Funding
Supplies and services for the clinical trial and
article processing charges are funded by Centagen, Inc.
Centagen had no role in the study design, data collection,
data analysis, or preparation of the manuscript.
Author’s Information
BV has a career in both academia and biotech (see
BV’s biographical summary in Wikipedia).
Trial Registration
The open label pilot study was registered retrospectively
on Feb. 8, 2017 (NCT03052491).
References
1. Giaimo S (2014) Evolution of aging through reduced
demographic stochasticity - an extension of the pleiotropy
theory to finite populations. Ecol Evol 4: 167-173.
2. Partridge L, Barton NH (1993) Evolution of aging: testing
the theory using Drosophila. Genetica 91: 89-98
3. Villeponteau B, Matsagas K, Nobles AC, et al. (2015) Herbal
supplement extends life span under some environmental
conditions and boosts stress resistance. PloS one 10: 0119068.
4. Akunuru S, Geiger H (2016) Aging, Clonality, and
Rejuvenation of Hematopoietic Stem Cells. Trends Mol Med
22: 701-712.
5. Nurkovic J, Volarevic V, Lako M, et al. (2016) Aging
of Stem and Progenitor Cells: Mechanisms, Impact on
Therapeutic Potential, and Rejuvenation. Rejuvenation Res
19: 3-12.
6. Ocampo A, Reddy P, Martinez-Redondo P, et al. (2016) In
Vivo Amelioration of Age-Associated Hallmarks by Partial
Reprogramming. Cell 167: 1719-1733.
7. Villeponteau B (2017) Still YL. Treating multiple antiaging
pathways improves health markers in open label clinical
study. Translational Medicine Communications 2.
8. Ruiz JR, Fiuza-Luces C, Garatachea N, et al. (2014)
Reduced mortality in former elite endurance athletes. Int J
Sports Physiol Perform 9: 1046-1049
9. Grimsmo J, Maehlum S, Moelstad P et al. (2011) Mortality
and cardiovascular morbidity among long-term endurance
male cross country skiers followed for 28-30 years. Scand J
Med Sci Sports 21: 351-358.
10. Nilsen C, Andel R, Fritzell J, et al. (2016) Work-related
stress in midlife and all-cause mortality: can sense of
coherence modify this association? Eur J Pub Health.
11. Kim J, Al-Mallah M, Juraschek SP, et al. (2016) the
association of clinical indication for exercise stress testing
with all-cause mortality: the FIT Project. Arch Med Sci: AMS
12: 303-309.
12. Tiainen K, Luukkaala T, Hervonen A et al. (2013)
Predictors of mortality in men and women aged 90 and older:
a nine-year follow-up study in the Vitality 90+ study. Age and
ageing 42: 468-475.
13. Bradford DW, Cunningham N (2016) Psychotic disorders
cause the greatest mortality disparity among mental disorders,
though more deaths are attributable overall to mood and
anxiety disorders. Evidence-based mental health 19: 58.
14. Osby U, Westman J, Hallgren J, et al. (2016) Mortality
trends in cardiovascular causes in schizophrenia, bipolar and
unipolar mood disorder in Sweden 1987-2010. Eur J Pub
Health.
15. Strandberg AY, Strandberg TE, Stenholm S, et al.
(2014) Low midlife blood pressure, survival, comorbidity,
and health-related quality of life in old age: the Helsinki
Businessmen Study. Am J Hypertens 32: 1797-1804.
page 9 of 9ISSN:XXXX-XXXX SFJHM, an open access journal
Volume 2 · Issue 1 · 1000010SF J Herb Med
Citation: Bryant Villeponteau (2018) Multipath Herbal Nutraceutical Improves Self-Reported Markers of Health and Life Expectancy in Clinical Study.
SF J Herb Med 2:1.
16. Ginzburg K, Kutz I, Koifman B, et al. (2016) Acute Stress
Disorder Symptoms Predict All-Cause Mortality Among
Myocardial Infarction Patients: a 15-Year Longitudinal
Study. Annals of behavioral medicine: a publication of the
Society of Behavioral Medicine. 50: 177-1786.
17. Carlsson AC, Starrin B, Gigante B, et al. (2014) financial
stress in late adulthood and diverse risks of incident
cardiovascular disease and all-cause mortality in women and
men. BMC public health 14: 17.
18. Redmond N, Richman J, Gamboa CM, et al. (2013)
Perceived stress is associated with incident coronary heart
disease and all-cause mortality in low- but not high-income
participants in the Reasons for Geographic And Racial
Differences in Stroke study. J Am Heart Assoc 2: 000447.
19. Atzmon G, Gabriely I, Greiner W, et al. (2002) Plasma
HDL levels highly correlate with cognitive function in
exceptional longevity. J Gerontol A Biol Sci Med Sci 57:
712-715.
20. Barter P (2004) HDL: a recipe for longevity.
Atherosclerosis Supplements 5: 25-31.
21. Laks R, Araujo LM, Almada Filho Cde M, et al. (2011)
the importance of HDL-C and CRP in cardiovascular risk
evaluation in longevous elderly individuals. Einstein 9: 397-
403.
22. Landi F, Russo A, Cesari M,et al. (2007) HDL-cholesterol
and physical performance: results from the ageing and
longevity study in the sirente geographic area (ilSIRENTE
Study). Age and ageing. 36: 514-520.
23. Fragoso CA, Gahbauer EA, Van Ness PH, et al. (2008)
Peak expiratory flow as a predictor of subsequent disability
and death in community-living older persons. J Am Geriatr
Soc 56: 1014-1020.
24. Roberts MH, Mapel DW (2012) Limited lung function:
impact of reduced peak expiratory flow on health status,
health-care utilization, and expected survival in older adults.
Am J Epidemiol 176: 127-134.
25. Cook NR, Evans DA, Scherr PA, et al. (1991) Peak
expiratory flow rate and 5-year mortality in an elderly
population. Am J Epidemiol 133: 784-794.
26. Klein BE, Moss SE, Klein R, et al. (2001) Wisconsin
Epidemiologic Study of Diabetic R. Peak expiratory flow rate:
relationship to risk variables and mortality: the Wisconsin
Epidemiologic Study of diabetic retinopathy. Diabetes care
24: 1967-1971.
27. Simons LA, McCallum J, Simons J (1997) Friedlander
Y Relationship of peak expiratory flow rate with mortality
and ischaemic heart disease in elderly Australians. Med J
Aust 166: 526-529.
Citation: Bryant Villeponteau (2018) Multipath Herbal Nutraceutical
Improves Self-Reported Markers of Health and Life Expectancy in
Clinical Study. SF J Herb Med 2:1.
